Cytosorbents (CTSO) Asset Writedowns and Impairment (2016 - 2026)
Cytosorbents' (CTSO) quarterly Asset Writedowns and Impairment came in at $38000.0 in Q2 2026, down 84.49% on a YoY basis from $245000.0 in Q2 2025, and down 87.33% quarter-over-quarter from $300000.0 in Q1 2026.
Powered by 
Analysis
Cytosorbents (CTSO) Asset Writedowns and Impairment (2016 - 2026) Analysis & Trends
Cytosorbents (CTSO) has reported Asset Writedowns and Impairment for 11 consecutive years, with $38000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Asset Writedowns and Impairment fell 84.49% year-over-year to $38000.0; the trailing twelve-month figure through Jun 2026 stood at $338000.0 (up 186.44% YoY), and the FY2025 full-year result was $253000.0, up 120.0% from the prior year.
- Asset Writedowns and Impairment eased to $38000.0 in Q2 2026 per CTSO's latest filing, from $300000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $305505.0 in Q1 2022 and bottomed at -$198000.0 in Q4 2024.
- Historically, Asset Writedowns and Impairment has averaged $133152.7 across 5 years, with a median of $180064.0 in 2023.
- The sharpest annual moves came in 2022 and 2024: Asset Writedowns and Impairment jumped 4141.19% in 2022, then sank 209.96% in 2024.
- Over 5 years, Asset Writedowns and Impairment stood at $204180.0 in 2022, then retreated by 11.81% to $180064.0 in 2023, then tumbled by 209.96% to -$198000.0 in 2024, then surged by 223.74% to $245000.0 in 2025, then tumbled by 84.49% to $38000.0 in 2026.
- According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $38000.0, $300000.0, and $245000.0 for Q2 2026, Q1 2026, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn |
| 10 | Cytosorbents | 20.00 Mn | 15.59 Mn | 7.05 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 38,000.00 |
| Mar 31, 2026 | 300,000.00 |
| Jun 30, 2025 | 245,000.00 |
| Mar 31, 2025 | 8,000.00 |
| Dec 31, 2024 | -198,000.00 |
| Sep 30, 2024 | 63,000.00 |
| Jun 30, 2024 | 185,704.00 |
| Mar 31, 2024 | 64,296.00 |
| Dec 31, 2023 | 180,064.00 |
| Sep 30, 2023 | 182,815.00 |
| Jun 30, 2023 | 181,582.00 |
| Mar 31, 2023 | 111,224.00 |
| Dec 31, 2022 | 204,180.00 |
| Jun 30, 2022 | 125,921.00 |
| Mar 31, 2022 | 305,505.00 |
| Dec 31, 2021 | -6,649.00 |
| Sep 30, 2021 | -16,552.00 |
| Jun 30, 2021 | 2,969.00 |
| Mar 31, 2021 | 19,720.00 |
| Dec 31, 2020 | -24,674.00 |